Calling The Ombudsman: Contacts With ANDA Sponsors, Investors On The Upswing
Executive Summary
Although the number of contacts from commercial sponsors and the pharmaceutical industry held steady in 2012, the CDER ombudsman’s office heard from more generic drug manufacturers and investors than in the prior year.